InvestorsHub Logo
Followers 0
Posts 149
Boards Moderated 0
Alias Born 01/26/2018

Re: WeeZuhl post# 283968

Thursday, 02/15/2018 5:08:22 AM

Thursday, February 15, 2018 5:08:22 AM

Post# of 402497

The judge didn't sided with Pfizer, because the litigation was dismissed by both parties... in fact, if anything, it was in favour of Watson because the litigation was dismissed with 'prejudice', which means Pfizer cannot sue Watson again for this.

Maybe if you read more about this deals you would realise how this works, because Watson/Actavis/Teva are the manufacturers of Embeda for Pfizer, they are and have been for the last 8 years, so the deal just brings money to Teva while they pursue their ANDA.

If you haven't seen an approval yet it is because Embeda was discontinued in 2011 until 2015, then it got its AD label in 2015... so other things happen thru these years that delayed any Gx Embeda


and as a note for all of those who wonder why there are no Gx ADFs yet, it is because FDA is waiting for the post-marketing studies from the current branded ADF to prove they work before they go and approve generics ;)



Yeah, it was settled alright. It was settled when the judge sided with Pfizer on the patent construction and then Pfizer told Watson to go fly a kite. Instead of wasting more money, Watson went and flew that kite. That was more than 6 years ago, and we haven't seen any generic Embeda yet, have we? So the "settlement" seems pretty one-sided. If they wanted to, as a part of the "settlement," Pfizer could have granted a bypass around their FDA exclusivity. The fact they didn't tells you the "settlement" did not favor Watson. That's as much as any of us know about the "settlement." I don't follow Teva, and so I don't know what they say about Embeda. I know they can say pretty much whatever they want in investor presentations under the protection of safe-harbor statements. Means nothing other than Teva trying to stir up investments.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News